RxDoctor Payments Data

Jeffery Grace, MD

Psychiatry · Buffalo, NYNPI 1841247921

Payments from drug & device makers

$3,212in general payments, 2019–2025

Across 153 payments — averaging $20.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$488
  • Neurocrine Biosciences, Inc.$385
  • Johnson & Johnson$369
  • Alkermes, Inc.$303
  • Otsuka America Pharmaceutical, Inc.$271
  • Indivior Inc.$264
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$3,15198%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,212 in reported general payments places this provider in the 85th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$14,162
Medicare patients
58
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine31$232,066
Invega SustennaPaliperidone Palmitate51$176,434
IngrezzaValbenazine Tosylate15$125,844
AristadaAripiprazole Lauroxil18$48,174
Clozapine488$39,068
VivitrolNaltrexone Microspheres13$20,559
RexultiBrexpiprazole12$19,605
Risperidone ErRisperidone Microspheres20$17,767
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$16,075
Risperdal ConstaRisperidone Microspheres19$13,176
Bupropion XlBupropion Hcl346$12,533
Fluphenazine Hcl48$12,127
Aripiprazole252$8,258
Fluphenazine Decanoate49$5,650
Quetiapine Fumarate296$5,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$488$232,06631 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$369$189,60970 claims
Neurocrine Biosciences, Inc.Ingrezza$385$125,84415 claims
Alkermes, Inc.Aristada, Vivitrol$303$68,73331 claims
Otsuka America Pharmaceutical, Inc.Rexulti$271$19,60512 claims
Almatica Pharma LLCSertraline Hcl$74$3,142281 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →